{"id":296214,"date":"2025-02-12T00:00:00","date_gmt":"2025-02-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0006-2024-biopharma-psoriatic-arthritis-unmet-need-unmet-need-psoriatic-arthritis-us-eu\/"},"modified":"2026-03-31T10:27:00","modified_gmt":"2026-03-31T10:27:00","slug":"unneim0006-2025-biopharma-psoriatic-arthritis-unmet-need-unmet-need-psoriatic-arthritis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0006-2025-biopharma-psoriatic-arthritis-unmet-need-unmet-need-psoriatic-arthritis-us-eu\/","title":{"rendered":"Psoriatic Arthritis &#8211; Unmet Need &#8211; Unmet Need &#8211; Psoriatic Arthritis (US\/EU)"},"content":{"rendered":"<p>The psoriatic arthritis (<abbr title=\"psoriatic arthritis\">PsA<\/abbr>) therapy market is on a growth trajectory, fueled by the disease\u2019s increasing prevalence, innovative treatment options, and heightened patient awareness. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors remain the primary treatment for <abbr title=\"psoriatic arthritis\">PsA<\/abbr> after conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr> failure; however, biologics such as <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors (Cosentyx, Taltz, Bimzelx) and <abbr title=\"interleukin\">IL<\/abbr>-23 inhibitors (Skyrizi) and targeted oral therapies such as <abbr title=\"phosphodiesterase IV\">PDE4<\/abbr> inhibitors and selective <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors (Otezla, Rinvoq) are increasingly challenging the dominance of <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors. Moreover, many patients do not respond adequately to these agents, necessitating alternative treatment strategies. There is a continuous need for effective treatments to address the complexities of <abbr title=\"psoriatic arthritis\">PsA<\/abbr>, including preventing joint damage. Recognizing these gaps in <abbr title=\"psoriatic arthritis\">PsA<\/abbr> treatment and focusing on product differentiation may be crucial to the success of a therapy in this space. This report outlines key unmet needs in the treatment of <abbr title=\"psoriatic arthritis\">PsA<\/abbr> and offers tools for strategic decision-making to compete successfully.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do current therapies perform on key treatment drivers and goals for <abbr title=\"psoriatic arthritis\">PsA<\/abbr>?<\/li>\n<li>When considering Humira, Cosentyx, Taltz, Otezla, Rinvoq, Bimzelx, Skyrizi, and others, which drug attributes are key influencers, which have limited impact, and which are hidden opportunities in <abbr title=\"psoriatic arthritis\">PsA<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the <abbr title=\"psoriatic arthritis\">PsA<\/abbr> market?<\/li>\n<li>What trade-offs across key drug attributes and price are acceptable to rheumatologists and dermatologists for a hypothetical new <abbr title=\"psoriatic arthritis\">PsA<\/abbr> drug?<\/li>\n<\/ul>\n<ul class=\"round-bullets\">\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European rheumatologists and dermatologists fielded in December 2024<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Amgen, UCB, Novartis, Eli Lilly<\/p>\n<p><strong>Key drugs:<\/strong> Humira, Cosentyx, Taltz, Otezla, Rinvoq, Bimzelx, Skyrizi<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (<abbr title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-296214","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-therapy-areas-rheumatology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296214\/revisions"}],"predecessor-version":[{"id":392127,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296214\/revisions\/392127"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}